Business Context and Reporting Period
This Form 8-K Current Report, dated March 24, 2021, pertains to Movano Inc. (trading symbol: MOVE), a medical device company incorporated in Delaware. The report details events occurring on March 24 and March 25, 2021, surrounding the company's Initial Public Offering (IPO) and significant executive leadership changes. Note: The request metadata references "Corvex, Inc.," but the filing text explicitly identifies the registrant as Movano Inc.
Key Financial Metrics
The filing reports the following financial data related to the IPO:
- Gross Proceeds: $48,875,000 from the sale of 9,775,000 shares of common stock.
- Offering Price: $5.00 per share.
- Underwriter Warrants: Issued warrants to purchase 956,973 shares at an exercise price of $6.00 per share.
- Operating Metrics: The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures for the reporting period.
Material Changes
The primary material changes reported are:
- Executive Leadership: Dr. John Mastrototaro, a current Board member, was appointed Chief Executive Officer (CEO), effective April 1, 2021. The current CEO, Michael Leabman, will transition to the role of Chief Technology Officer (CTO).
- Capital Structure: The company completed its IPO, transitioning from a private to a public entity listed on The Nasdaq Stock Market LLC.
- Corporate Governance: The company filed a Third Amended and Restated Certificate of Incorporation and adopted Amended and Restated Bylaws effective in connection with the IPO.
Guidance, Outlook, and Risks
Management Commentary: The filing highlights Dr. Mastrototaro's extensive background in the medical device industry, including over 30 years of experience with Medtronic and Orthosensor, focusing on innovation in diabetes care and data analytics. The appointment is framed as a strategic move to leverage his experience in bringing new products to market.
Risks and Contingencies: The filing does not explicitly list risk factors or contingencies within the text provided, though it references the Prospectus for a full description of the Certificate of Incorporation and Bylaws. The company is designated as an "emerging growth company."
Investor Verification Checklist
- Verify the final net proceeds after deducting underwriting discounts and offering expenses, as only gross proceeds ($48,875,000) are stated.
- Review the full text of the Third Amended and Restated Certificate of Incorporation (Exhibit 3.1) and Amended and Restated Bylaws (Exhibit 3.2) for specific governance provisions.
- Confirm the terms of the underwriter warrants (956,973 shares at $6.00 exercise price) and their impact on potential dilution.
- Examine the Prospectus (File No. 333-252671) for detailed financial statements and risk factors not included in this 8-K summary.